Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Lembeck, F; Griesbacher, T; Eckhardt, M; Henke, S; Breipohl, G; Knolle, J.
New, long-acting, potent bradykinin antagonists.
Br J Pharmacol. 1991; 102(2):297-304 Doi: 10.1111/j.1476-5381.1991.tb12169.x [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

Führende Autor*innen der Med Uni Graz
Lembeck Fred
Co-Autor*innen der Med Uni Graz
Griesbacher Thomas
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
1. Three new bradykinin (BK) antagonists, D-Arg0-Hyp3-Thi5-D-Tic7-Oic8-BK (compound I), D-Arg0-Hyp3-D-Tic7-Oic8-BK (compound II), and Arg(Tos)1-Hyp3-Thi5-D-Tic7-Oic8-BK (compound III), were tested against the effects of BK in 9 bioassay preparations including visceral smooth muscles, vasoconstriction, plasma protein extravasation, release of prostaglandin E2, bronchoconstriction, and stimulation of afferent C-fibre nociceptors. In some of these tests the effects of the new compounds were compared with those of the antagonist D-Arg0-Hyp2-Thi5,8-D-Phe7-BK (compound IV), described by Stewart & Vavrek (1987). 2. For all bioassays the general rank order of potency of the compounds was found to be I greater than II greater than III much greater than IV. The new antagonists were long-acting; in some bioassays their effects outlasted the duration of the experiment. 3. The inhibitory effects of the new BK antagonists were specific for BK; actions of noradrenaline, angiotensin II, acetylcholine or histamine were unaffected by the antagonists. They did not stimulate the release of histamine or prostaglandins. An agonistic effect was observed only with very high concentrations of compounds I and II in the plasma protein extravasation test. 4. The long duration of action of the new BK antagonists is probably due to a high and long-lasting affinity to the BK receptors. A high resistance of the antagonists to enzymatic destruction may be another reason. 5. The new BK antagonists will be valuable tools for the investigation of the pathophysiological role of BK. In addition they may offer a potential for therapeutic applications.
Find related publications in this database (using NLM MeSH Indexing)
Afferent Pathways - drug effects
Animals - drug effects
Blood Proteins - metabolism
Bradykinin - analogs and derivatives
Bronchi - drug effects
Dinoprostone - secretion
Female - secretion
Guinea Pigs - secretion
Male - secretion
Muscle Contraction - drug effects
Muscle, Smooth - drug effects
Nociceptors - drug effects
Rabbits - drug effects
Rats - drug effects
Vasoconstriction - drug effects

© Med Uni Graz Impressum